United Therapeutics Corporation
$ 503.60
-5.89%
26 Feb - close price
- Market Cap 24,200,573,000 USD
- Current Price $ 503.60
- High / Low $ 532.25 / 496.44
- Stock P/E 17.89
- Book Value 153.61
- EPS 29.91
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.13 %
- ROE 0.20 %
- 52 Week High 537.19
- 52 Week Low 266.98
About
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Analyst Target Price
$538.58
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-25 | 2025-10-29 | 2025-07-29 | 2025-04-29 | 2025-02-19 | 2024-10-30 | 2024-07-31 | 2024-05-01 | 2024-02-21 | 2023-11-01 | 2023-08-02 | 2023-05-03 |
| Reported EPS | 7.7 | 7.16 | 6.41 | 6.6296 | 6.19 | 6.39 | 5.85 | 6.17 | 4.36 | 5.38 | 5.24 | 4.86 |
| Estimated EPS | 7.1 | 7.32 | 7.35 | 6.66 | 6.2668 | 6.43 | 6.4 | 5.65 | 4.19 | 5.04 | 4.51 | 4.52 |
| Surprise | 0.6 | -0.16 | -0.94 | -0.0304 | -0.0768 | -0.04 | -0.55 | 0.52 | 0.17 | 0.34 | 0.73 | 0.34 |
| Surprise Percentage | 8.4507% | -2.1858% | -12.7891% | -0.4565% | -1.2255% | -0.6221% | -8.5938% | 9.2035% | 4.0573% | 6.746% | 16.1863% | 7.5221% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 7.44 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: UTHR
2026-02-25 13:53:00
United Therapeutics (UTHR) shares fell almost 5% after the company reported Q4 2025 earnings that beat analyst estimates but revenue that missed expectations. While adjusted EPS outpaced forecasts, revenue growth was modest at 2% year-over-year, reaching $636 million against an expected $654 million. The company's full-year outlook for 2026 also projected revenue below analyst consensus.
2026-02-25 13:53:00
United Therapeutics (NASDAQ:UTHR) reported Q4 CY2025 results, missing Wall Street's revenue expectations with $790.2 million but surpassing GAAP EPS estimates at $7.70 per share. Despite solid five-year revenue growth, analysts project flat revenue for the next 12 months. The company's operating margin decreased year-on-year, though its five-year trend showed strong profitability.
2026-02-25 12:53:00
United Therapeutics Corp. (NASDAQ:UTHR) reported record annual revenue of $3.18 billion for 2025, an 11% increase, despite missing Wall Street's Q4 revenue estimates with $790.2 million against an anticipated $829.3 million. The company's non-GAAP diluted EPS of $7.70 for Q4 surpassed estimates, driven largely by its Tyvaso franchise. While the market reaction was muted initially, the company anticipates "transformational growth" from upcoming clinical data readouts.
2026-02-25 11:53:00
United Therapeutics Corporation announced record revenues and significant growth for the fourth quarter and full year ending December 31, 2025. The company reported total revenues of $3.18 billion for the full year, an 11% increase, and a net income of $1.33 billion. Key drivers included strong performance from its Tyvaso product line and ongoing strategic initiatives like share repurchases, with management anticipating continued double-digit revenue growth.
2026-02-24 21:51:59
This article details insider trading activity for UNITED THERAPEUTICS Corp (UTHR) by President and COO Michael Benkowitz. The report shows that Benkowitz, through associated trusts, exercised stock options and simultaneously sold the shares in open-market transactions for $472.126 per share on February 23, 2026. These transactions were conducted under a pre-established Rule 10b5-1 trading plan and represent its final activities.
2026-02-24 14:51:59
United Therapeutics (UTHR) is scheduled to announce its Q4 earnings on February 25 before market open. The consensus EPS estimate is $7.24, with a revenue forecast of $811.35 million, marking a 10.3% year-over-year increase despite mixed revisions on estimates. Investors will be closely watching the report to assess the company's competitive standing and strategic direction within the biopharmaceutical sector.
